Professor Kwang-Hyun Cho's research team has recently been highlighted for their work on developing an original technology ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

Jack Craig took the reins as president and chief executive officer of CNL last April, assuming that role from Joe McBrearty, who had helmed the company for four years prior to that.